Abstract
Abstract
Leishmaniasis is a parasitic infection expressing different clinical phenotypes. Visceral leishmaniasis (VL) is considered an opportunistic infection among people with human immunodeficiency virus (HIV). The objective of this review was to identify published data on the prevalence of Leishmania spp. infection among PWH and to define particular determinants that affect critically the epidemiological characteristics of VL-HIV coinfection and, potentially, its burden on public health. Two independent reviewers conducted a systematic literature search until June 30, 2022. Meta-analyses were conducted using random-effects models to calculate the summary prevalence and respective 95% confidence intervals (CI) of leishmaniasis among PWH. Meta-regression analysis was performed to investigate the impact of putative effect modifiers, such as the mean CD4 cell count, on the major findings. Thirty-four studies were eligible, yielding a summary prevalence of 6% (95%CI, 4–11%) for leishmaniasis (n = 1583) among PWH (n = 85,076). Higher prevalence rates were noted in Asia (17%, 95%CI, 9–30%) and America (9%, 95%CI, 5–17%) than in Europe (4%, 95%CI, 2–8%). Prevalence rates were significantly mediated by the age, sex, and CD4 cell count of participants. Heterogeneity remained significant in all meta-analyses (p < 0.0001). In the majority of included studies, people were coinfected with HIV and Leishmania species associated with VL, as opposed to those associated with cutaneous leishmaniasis. No sign of publication bias was shown (p = 0.06). Our summary of published studies on leishmaniasis among PWH is important to provide prevalence estimates and define potential underlying factors that could guide researchers to generate and further explore specific etiologic hypotheses.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference62 articles.
1. Handler MZ, Patel PA, Kapila R, Al-Qubati Y, Schwartz RA (2015) Cutaneous and mucocutaneous leishmaniasis: clinical perspectives. J Am Acad Dermatol 73(6):897–908. https://doi.org/10.1016/j.jaad.2014.08.051
2. Burza S, Croft SL, Boelaert M (2018) Leishmaniasis. Lancet 392(10151):951–970. https://doi.org/10.1016/S0140-6736(18)31204-2
3. Ruiz-Postigo JA, Jain S, Mikhailov A, Maia-Elkhoury AN, Valadas S, Warusavithana S, Osman M, Lin Z,
Beshah A, Yajima A, Gasimovg E (2021) Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap. WHO, Weekly Epidemiological Register 35(96):401–420
4. Alvar J, Yactayo S, Bern C (2006) Leishmaniasis and poverty. Trends Parasitol 22(12):552–557. https://doi.org/10.1016/j.pt.2006.09.004
5. van Griensven J, Carrillo E, López-Vélez R, Lynen L, Moreno J (2014) Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 20(4):286–299. https://doi.org/10.1111/1469-0691.12556
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献